MGC Pharmaceuticals (ASX:MXC) First Half 2023 Results
Key Financial Results
Revenue: AU$2.66m (up 3.8% from 1H 2022).
Net loss: AU$10.9m (loss widened by 46% from 1H 2022).
AU$0.004 loss per share (further deteriorated from AU$0.003 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MGC Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Australia.
The company's shares are down 16% from a week ago.
You should learn about the 7 warning signs we've spotted with MGC Pharmaceuticals (including 4 which can't be ignored).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here